Equity Profile

AUPH

AURINIA PHARMACEUTIC Equity

Health CareBiotechnology$2.0B

Jul30Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Aurinia Pharmaceuticals (AUPH) is a biotechnology company focused on developing therapies for kidney diseases, particularly lupus nephritis. With a market cap of $2 billion, it operates in the health care sector, addressing significant unmet medical needs in chronic conditions.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, and investors will be keen to see if Aurinia can continue its trend of beating estimates.

$0.25

Revenue Growth

While specific revenue estimates are not available, any growth in revenue will indicate the company's ability to expand its market presence and sales.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

AUPH Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+142.91%

Avg Stock Reaction

+0.41%

Last Quarter Recap

In Q1 2026, Aurinia reported an EPS of $0.25, exceeding expectations by 38.89%. However, the stock dropped 6.80% the following day, indicating market skepticism despite the positive earnings surprise.

Management Promises & Guidance

Focus on expanding the market for its lupus nephritis treatment.
Commitment to ongoing clinical trials and research.
Plans to enhance operational efficiencies.

Expectations

Wall Street Expectations

Overall, expectations are mixed as Aurinia has shown a strong track record of beating EPS estimates, but recent stock reactions suggest caution among investors.

Bull Case

If Aurinia continues its trend of beating EPS estimates and shows strong revenue growth, it could boost investor confidence and drive the stock higher.

Bear Case

On the other hand, if the company fails to meet expectations or provides weak guidance, it could lead to a significant decline in stock price.

Key Metrics to Watch

Earnings Per Share (EPS)

$0.25

EPS is a key indicator of the company's profitability and financial health, and investors will be keen to see if Aurinia can continue its trend of beating estimates.

Revenue Growth

N/A

While specific revenue estimates are not available, any growth in revenue will indicate the company's ability to expand its market presence and sales.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Aurinia provide specific revenue growth figures for its lupus nephritis treatment?

This will be crucial for understanding the company's market performance and future potential.

What are the updates on ongoing clinical trials?

Investors will be looking for insights into the pipeline and any potential impacts on future earnings.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Aurinia's potential for revenue growth due to its strong pipeline and recent clinical trial successes.

Supporting Evidence

Aurinia has consistently beaten EPS estimates, indicating stronger operational performance than anticipated.

The options market is pricing a significant move, suggesting that investors expect more volatility than historical patterns would suggest.

Key Risk

If the company reports strong revenue growth, it could challenge the current cautious sentiment in the market.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating Aurinia's ability to maintain its growth trajectory amidst competitive pressures in the biotech space.

Bull Confirmed If

Aurinia reports an EPS of $0.30 or higher, indicating strong profitability.

Bear Confirmed If

An EPS below $0.20 would raise concerns about the company's financial health.

Pre-Earnings Positioning

Options Market

Implied Move

±23.81%

Historical Avg

±5.3%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings report.

Options are pricing ±23.8% while AUPH has averaged ±5.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

38.5%

Calls (23K)P/C Ratio: 0.02Puts (400)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Aurinia beats expectations, history suggests the stock could rise by around 1.03% on the following day, confirming positive market sentiment.

In-Line / Cautious

If results are in line but management provides cautious commentary, the stock may experience muted movement as investors reassess their outlook.

Miss

A miss could lead to a decline of about 1.44%, reflecting investor disappointment and concerns about future performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any specific revenue guidance for the lupus nephritis treatment.
2Updates on clinical trial results and timelines.
3Management's outlook on market competition.
4Details on operational efficiencies and cost management.
5Insights into future product pipeline developments.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

Insider activity

PreviewView

Jul

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, and investors will be keen to see if Aurinia can continue its trend of beating estimates.

$0.25

Revenue Growth

While specific revenue estimates are not available, any growth in revenue will indicate the company's ability to expand its market presence and sales.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

AUPH Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+142.91%

Avg Stock Reaction

+0.41%

Last Quarter Recap

Management Promises & Guidance

Focus on expanding the market for its lupus nephritis treatment.
Commitment to ongoing clinical trials and research.
Plans to enhance operational efficiencies.

Expectations

Wall Street Expectations

Overall, expectations are mixed as Aurinia has shown a strong track record of beating EPS estimates, but recent stock reactions suggest caution among investors.

Bull Case

If Aurinia continues its trend of beating EPS estimates and shows strong revenue growth, it could boost investor confidence and drive the stock higher.

Bear Case

On the other hand, if the company fails to meet expectations or provides weak guidance, it could lead to a significant decline in stock price.

Key Metrics to Watch

Earnings Per Share (EPS)

$0.25

EPS is a key indicator of the company's profitability and financial health, and investors will be keen to see if Aurinia can continue its trend of beating estimates.

Revenue Growth

N/A

While specific revenue estimates are not available, any growth in revenue will indicate the company's ability to expand its market presence and sales.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Aurinia provide specific revenue growth figures for its lupus nephritis treatment?

This will be crucial for understanding the company's market performance and future potential.

What are the updates on ongoing clinical trials?

Investors will be looking for insights into the pipeline and any potential impacts on future earnings.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Aurinia's potential for revenue growth due to its strong pipeline and recent clinical trial successes.

Supporting Evidence

Aurinia has consistently beaten EPS estimates, indicating stronger operational performance than anticipated.

The options market is pricing a significant move, suggesting that investors expect more volatility than historical patterns would suggest.

Key Risk

If the company reports strong revenue growth, it could challenge the current cautious sentiment in the market.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating Aurinia's ability to maintain its growth trajectory amidst competitive pressures in the biotech space.

Bull Confirmed If

Aurinia reports an EPS of $0.30 or higher, indicating strong profitability.

Bear Confirmed If

An EPS below $0.20 would raise concerns about the company's financial health.

Pre-Earnings Positioning

Options Market

Implied Move

±23.81%

Historical Avg

±5.3%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings report.

Options are pricing ±23.8% while AUPH has averaged ±5.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

38.5%

Calls (23K)P/C Ratio: 0.02Puts (400)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Aurinia beats expectations, history suggests the stock could rise by around 1.03% on the following day, confirming positive market sentiment.

In-Line / Cautious

If results are in line but management provides cautious commentary, the stock may experience muted movement as investors reassess their outlook.

Miss

A miss could lead to a decline of about 1.44%, reflecting investor disappointment and concerns about future performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any specific revenue guidance for the lupus nephritis treatment.
2Updates on clinical trial results and timelines.
3Management's outlook on market competition.
4Details on operational efficiencies and cost management.
5Insights into future product pipeline developments.